Cognition Therapeutics, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| CGTX | ACOG | GANX | VYGR | PMN | CRVO | |
|---|---|---|---|---|---|---|
| Market cap | 64.98M | 185.77M | 48.44M | 115.23M | 31.57M | 23.59M |
| P/E (TTM) | — | — | — | — | — | — |
| Forward P/E | -3.1 | -13.8 | -1.6 | -1.5 | -0.8 | -1.1 |
| Price/book | 2.0 | 3.5 | 4.3 | 0.7 | 0.6 | 0.9 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −58.86% | +49.65% | −41.58% | −55.69% | −63.90% | −78.60% |
| Today | −2.32% | +4.02% | −3.48% | +2.19% | +3.23% | +0.65% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All CGTX news ›Cognition Therapeutics Announces Issuance of Composition of Matter Patent, Extending Protection for Zervimesine (CT1812) Through 2045
Investor Relations / Press Releases – An additional five years of patent protection may be possible through a standard extension – The ‘979 patent offers the following protections: The USAN Council has adopted zervimesine as the United…
Cognition Therapeutics Announces Alignment with FDA on Pivotal Phase 3 Trial of Zervimesine (CT1812) in Dementia with Lewy Bodies
Cognition Therapeutics Announces Alignment with FDA on GlobeNewswire
Cognition Therapeutics, Inc.(NasdaqCM: CGTX) added to Russell 3000E Index
Cognition Therapeutics, Inc. added to Russell 3000E Index... Biotechnology & Medical Research Cognition Therapeutics, Inc.(NasdaqCM:CGTX) added to Russell 3000E Index Latest news about Cognition Therapeutics, Inc. Chart Cognition…
Transcript : Cognition Therapeutics, Inc., Q4 2025 Earnings Call, Mar 26, 2026
Presentation Operator MessageOperator Hello, and welcome, everyone, joining today's Cognition Therapeutics Fourth Quarter and Full Year 2025 Earnings Call. [Operator Instructions] Please note, this... Transcript : Cognition Therapeutics,…
Cognition Therapeutics, Inc.: Relative Strength Chart - Stock Nasdaq
Compare Cognition Therapeutics, Inc. with the company of your choice via a Relative Strength chart. Real-time CGTX price, Nasdaq stock exchange Relative Strength Chart Cognition Therapeutics, Inc. Biotechnology & Medical Research All…
Cognition Therapeutics wins patent for zervimesine through 2045
The United States Patent and Trademark Office has granted Cognition Therapeutics a patent covering a novel crystalline form, or polymorph, of zervimesine (CT1812), U.S. Patent No. 12,759,979, with a natural expiration in 2045 and potential…
Cognition Therapeutics Receives Patent Allowance for Polymorphic Crystalline Form of Zervimesine
Cognition Therapeutics said Tuesday it has received a notice of allowance from the US Patent and Trademark Office for its patent application covering a polymorphic crystalline form of zervimesine,... Biotechnology & Medical Research…
Cognition Therapeutics Aligns on Key Aspects of Pivotal Study for Zervimesine in DLB Psychosis Following Receipt of FDA Meeting Minutes
Cognition Therapeutics, Inc. received written feedback from the U.S. Food and Drug Administration following its recent meeting. The FDA agreed that psychosis associated with dementia with Lewy bodies... received written feedback from the…
Cognition Therapeutics Presents Evidence Of Zervimesine?s Impact On Neuropsychiatric Symptoms Of Dementia With Lewy Bodies
Cognition Therapeutics, Inc. presented an analysis from the Phase 2 COG1201 SHIMMER study of zervimesine in dementia with Lewy bodies at the AD/PD 2026 Alzheimer's & Parkinson's Diseases... presented an analysis from the Phase 2 COG1201…
Cognition Therapeutics, Inc. Completes Meeting With FDA For Zervimesine In Dementia With Lewy Bodies With Psychosis
Cognition Therapeutics, Inc. conducted a planned meeting with the U.S. Food and Drug Administration on May 20, 2026. The objective of this meeting was to review results from the Phase 2 study of... conducted a planned meeting with the U.S…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- marketscreener.com4
- globenewswire.com2
- ir.cogrx.com1
- longevity.technology1
- stocktitan.net1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 9 articles, not a forecast.